Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.

Ciraulo DA, Hitzemann RJ, Somoza E, Knapp CM, Rotrosen J, Sarid-Segal O, Ciraulo AM, Greenblatt DJ, Chiang CN.

J Clin Pharmacol. 2006 Feb;46(2):179-92.

PMID:
16432270
2.

Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

Chiang CN, Hawks RL.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S39-47. Review.

PMID:
12738349
3.

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Mendelson J, Jones RT.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. Review.

PMID:
12738348
4.
5.

Buprenorphine: how to use it right.

Johnson RE, Strain EC, Amass L.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S59-77. Review.

PMID:
12738351
6.

Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.

Soyka M.

Expert Opin Drug Deliv. 2012 Nov;9(11):1409-17. doi: 10.1517/17425247.2012.729574. Epub 2012 Sep 26. Review.

PMID:
23013384
7.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
8.

Buprenorphine for opioid dependence.

Milne M, Crouch BI, Caravati EM.

J Pain Palliat Care Pharmacother. 2009;23(2):153-5. doi: 10.1080/15360280902900869. Review.

PMID:
19492216
9.

The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.

Mammen K, Bell J.

Expert Opin Pharmacother. 2009 Oct;10(15):2537-44. doi: 10.1517/14656560903213405. Review.

PMID:
19708849
10.

Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences.

MĂ©garbane B, Hreiche R, Pirnay S, Marie N, Baud FJ.

Toxicol Rev. 2006;25(2):79-85. Review.

PMID:
16958555
11.

Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals.

Webster LR, Camilleri M, Finn A.

Subst Abuse Rehabil. 2016 Jun 14;7:81-6. doi: 10.2147/SAR.S100998. eCollection 2016. Review.

12.

Buprenorphine.

Lober C.

Conn Med. 1988 May;52(5):285-7. Review. No abstract available.

PMID:
3042275

Supplemental Content

Support Center